drugset / Trial / NCT02644915

Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients

NCT02644915

RandomizedParallel-groupDouble-blindPrevention

Summary

Ischemia-reperfusion (I/R) injury is a prominent cause of delayed graft function(DGF) after kidney transplantation. Reactive oxygen species play a crucial role in I/R injury. Edaravone is a synthetic radical scavenger that has been used in acute stroke. Some animal experiments have revealed its beneficial effects against I/R injury, our goal is therefore to investigate the effectiveness of a recipient pretreatment with Edaravone at reducing the occurrence of DGF after kidney transplantation.

Timeline

Start
2016-03
Primary completion
2016-09
Completion
2016-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Edaravone Unknown 30 mg

Indications

No indication recorded.